View Older Stories
-
Novo CEO Says Bid For Metsera Is Higher Than Pfizer's Is Today
-
Novo Nordisk Is Said To Sweeten Bid For Obesity Startup Metsera - Bloomberg
-
Pfizer vows to continue Metsera legal fight after court denies restraining order
-
Pfizer Preps Improved Offer In Metsera Bidding War - WSJ
-
Pfizer Denied Temporary Block On Novo Nordisk’s Metsera Bid - Bloomberg
-
Pfizer Drops Demand That Metsera Denounce Novo Bid: Metsera - Bloomberg
-
FTC Says Novo-Metsera Bid Raises Merger Filing Concerns - Bloomberg
-
Pfizer has removed conditions on sale of Arch Venture shares and Metsera public statements from its Metsera bid - Pfizer letter to court
-
Pfizer (PFE) CEO: our bid for Metsera has taken into consideration that prices of GLP-1 will probably start going down - Conference Call
-
Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies - FT
-
Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
-
Metsera (MTSR) Halted, News Pending
-
Metsera responds to Pfizer litigation amid competing acquisition bids
-
Pfizer files second lawsuit against Novo Nordisk over Metsera acquisition
-
Metsera responds to Pfizer litigation, will address claims in court
-
Pfizer sues Metsera directors and Novo Nordisk over merger breach
-
Pfizer gets early FTC clearance for Metsera acquisition
-
Pfizer mulls suing Metsera, Novo Nordisk over topping bid - Semafor
-
Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
-
Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
-
Novo Nordisk makes $9 billion bid for Metsera amid Pfizer deal
-
Pfizer calls Novo Nordisk's Metsera bid reckless and illegal
-
Novo Nordisk submits $6.5 billion offer for Metsera
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Wells Fargo Downgrades Metsera Inc (MTSR) to Equal Weight
-
Leerink Partners Downgrades Metsera Inc (MTSR) to Market Perform
-
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
-
BTIG on Pfizer (PFE) deal for Metsera (MTSR): 'representative of large pharma's strong interest in the obesity and metabolic disease platforms'
-
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
-
Metasource Group, Inc. (MTSR) call put ratio call put ratio 2.7 calls to 1 put into Pfizer (PFE) to acquire Metsera for $47.50 per share in cash
-
Pfizer (PFE) Nears Potential $7.3 bln Takeover Of Metsera- FT
-
Cantor Fitzgerald Reiterates Overweight Rating on Metsera Inc (MTSR)
-
Leerink Partners Starts Metsera Inc (MTSR) at Outperform
-
Cantor Fitzgerald Reiterates Overweight Rating on Metsera Inc (MTSR)
-
Metsera, Inc. (MTSR) Misses Q2 EPS by 3c
-
Chardan Comments on iBio, Inc. (IBIO)
-
Wells Fargo Starts Metsera Inc (MTSR) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Metsera Inc (MTSR)
-
Metasource Group, Inc. (MTSR) Announces Positive Phase 1 Data for MET-233i
-
Cantor Fitzgerald Reiterates Overweight Rating on Metsera Inc (MTSR)
-
Metsera, Inc. (MTSR) Reports Q1 Loss of $1.03
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Cantor Fitzgerald says more options, newer targets will expand obesity market
-
Cantor Fitzgerald Starts Metsera Inc (MTSR) at Overweight
-
BofA Securities Starts Metsera Inc (MTSR) at Buy
-
Guggenheim Starts Metsera Inc (MTSR) at Buy
-
JMP Securities Biotechnology Overview
